Clinical Trials Logo

Malignant Pleural Mesothelioma clinical trials

View clinical trials related to Malignant Pleural Mesothelioma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06318286 Not yet recruiting - Clinical trials for Malignant Pleural Mesothelioma

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

PENINSULA
Start date: March 13, 2024
Phase: Phase 2
Study type: Interventional

In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma.

NCT ID: NCT05425576 Not yet recruiting - Clinical trials for Malignant Pleural Mesothelioma

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Start date: June 2025
Phase: Phase 2
Study type: Interventional

This is a study of OT-101, a TGF-b2 inhibitor in combination of pembrolizumab in patients with malignant pleural mesothelioma. Both efficacy assessment, and safety and tolerability of various dose of OT-101 in combination of pembrolizumab are evaluated.

NCT ID: NCT04713761 Not yet recruiting - Clinical trials for Malignant Pleural Mesothelioma

Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma

Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, open, II phase study to evaluate the safety and efficacy of Toripalimab, pemetrexed and carboplatin in the treatment of locally advanced malignant MPM in 15 newly diagnosed patients with locally advanced malignant MPM.

NCT ID: NCT02761863 Not yet recruiting - Clinical trials for Malignant Pleural Mesothelioma

Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma

Start date: July 30, 2019
Phase: N/A
Study type: Observational

This is a prospective study evaluating the effect of expression of CD74 and VEGF on outcome of treatment in patients with malignant pleural mesothelioma receiving Pemetrexed/Platinum protocol. The paraffin blocks of the patients will be tested for CD74 and VEGF before starting treatment using IHC and the results will be correlated with the outcome of treatment during evaluation.